Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) and Homology Medicines (NASDAQ:FIXX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.
Analyst Recommendations
This is a breakdown of current recommendations for Actinium Pharmaceuticals and Homology Medicines, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Actinium Pharmaceuticals | 0 | 0 | 4 | 0 | 3.00 |
Homology Medicines | 0 | 1 | 7 | 0 | 2.88 |
Actinium Pharmaceuticals currently has a consensus price target of $45.00, suggesting a potential upside of 471.07%. Homology Medicines has a consensus price target of $28.3750, suggesting a potential upside of 200.58%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Actinium Pharmaceuticals is more favorable than Homology Medicines.
Earnings and Valuation
This table compares Actinium Pharmaceuticals and Homology Medicines' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Actinium Pharmaceuticals | N/A | N/A | $-21,900,000.00 | N/A | N/A |
Homology Medicines | $1.67 million | 255.86 | $-103,920,000.00 | ($2.47) | -3.82 |
Actinium Pharmaceuticals has higher earnings, but lower revenue than Homology Medicines.
Profitability
This table compares Actinium Pharmaceuticals and Homology Medicines' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Actinium Pharmaceuticals | N/A | -77.96% | -64.62% |
Homology Medicines | -5,386.00% | -57.92% | -45.33% |
Volatility and Risk
Actinium Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Homology Medicines has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500.
Insider & Institutional Ownership
17.6% of Actinium Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of Homology Medicines shares are held by institutional investors. 1.5% of Actinium Pharmaceuticals shares are held by insiders. Comparatively, 33.4% of Homology Medicines shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Homology Medicines beats Actinium Pharmaceuticals on 6 of the 11 factors compared between the two stocks.